Select Page

Allergic Fungal Sinusitis

Establishing the diagnosis

Etiology

  • Immunoglobulin E (Ig-E) mediated, eosinophil predominant hypersensitivity reaction to fungi in paranasal sinuses
  • Mycotoxins from dying fungus can stimulate release of proinflammatory cytokines (Eur Arch Oto-Rhino-Laryngol 2012; 269:1155).
  • Aspergillus species the most common pathogen
    • Aspergillus fumigatis and flavis
  • Other reported fungal pathogens include trichosporon species, and from the demitaceous (dark-pigmented) family including Curvularia, Bipolaris (Am J Ophthalmol 1988; 105:366), Alternaria (Am J Ophthalmol 1999; 127:189).

Epidemiology

  • Younger patients, second and third decades
  • No gender predilection
  • 90% have history of allergic rhinitis

History

  • Chronic sinus pressure
  • Chronic nasal discharge with thick mucus
  • History of nasal polyposis
  • Allergy
  • Asthma
  • Diplopia with orbital and/or intracranial extension
  • Visual loss (Br J Ophthalmol 1988; 72:127)
  • Tearing
  • Periorbital erythema and edema
  • Pertinent negatives: There should be no history of immunosuppression.

Clinical features

  • Large quantities of allergic mucin in the paranasal sinuses
    • thick mucus
    • necrotic eosinophils
    • Charcot-Leyden crystals
    • sparse fungal mycelial elements
  • Nasal polyposis
  • Inflammatory mass extends into orbit and intracranially
  • Proptosis
  • Ptosis
  • Extraocular motility limitation
  • Orbital apex syndrome
  • Cavernous sinus thrombosis
  • Visual loss from suprasellar compression by inflammatory mass (J Neuro-ophthalmol 2012; 32:197)
    • Surgical decompression of optic nerve might be indicated (J Otolaryngol Otol 2011; 125:381).
  • Nasolacrimal duct obstruction (OPRS 2011; 27:e98)
  • Chronic dilation of the lacrimal sac (Orbit 2013; 32:143)
    • Allergic mucin with eosinophilia fills the dilated lacrimal sac and adjoining sinuses.
  • Sixth nerve palsy — potentially reversible (Am J Rhinol Allerg 2013; 27:432)
    • The abducens nerve is most medial in the cavernous sinus, making it highly susceptible to sphenoid sinus disease.

Testing

(Curr Opin Allerg Clin Immunol 2012; 12:629)

  • Examination of tissue and mucus is required to make the diagnosis
  • With orbital involvement, CT scan demonstrates inflammatory mass eroding into the orbit and thick allergic mucin in sinuses
  • MRI demonstrates isointense or hypointense inflammatory tissue on T1, hypointense and flow void on T2 because allergic mucin is thick and dry
  • Histopathologic evidence of non-invasive fungal sinusitis
  • Histopathology of allergic mucin
  • Absence of granulomas (differentiates from granulomatous sinusitis)
  • Absence of necrosis or giant cell reaction (differentiates from invasive fungal sinusitis)
  • Peripheral eosinophilia
  • High total serum Ig-E
  • Ig-E specific for particular fungi
  • Fungus in allergic mucin is dying and fragmented, not vital, therefore difficult to culture (Curr Opin Allerg Clin Immunol 2012; 12:629)

Risk factors

  • Hot, humid climate
  • Atopy might be a predisposing factor.
  • Cluster of cases has been observed post-hurricane season (J Neuro-ophthalmol 2012; 32:197).

Differential diagnosis

  • Chronic rhinosinusitis can also be caused by (Laryngoscope 2013; 123:S15-27)
    • Aspirin exacerbated respiratory disease
      • Triad of aspirin sensitivity, asthma, and nasal polyps
    • Asthmatic sinusitis with or without allergy
      • Reactive airway disease with or without positive allergy test
    • Nonasthmatic sinusitis with or without allergy
      • No reactive airway disease with or without positive allergy test
    • Cystic fibrosis — positive sweat test or genetic evaluation
  • Other fungal sinus diseases and bacterial sinus

Patient management: treatment and follow-up

Natural history

  • Patients with long standing allergic fungal sinusitis can develop invasive fungal sinusitis including invasive intracranial aspergillosis (Med Mycol 2012; 50:179).
  • Both orbits can be affected by very large inflammatory mass (Arch Ophthalmol 1996; 114:767).
  • Some are mixed cases of invasive and allergic fungal sinusitis.

Medical therapy

  • Oral steroids are recommended (Int Forum Allerg Rhinol 2013; 3:104).
    • Typically requires 3–4 weeks of treatment
  • Intranasal corticosteroids as adjunctive therapy
  • Oral antifungal medication might be needed despite absence of invasive infection.
    • Most cases reported in the ophthalmic literature have not been treated with oral antifungal medication (OPRS 2000; 16:72).
    • Utility and safety of oral antifungal treatment for allergic fungal sinusitis has been questioned (Am J Rhinol Allerg 2012; 26:141).
      • Based on meta-analysis of 6 double-blind randomized trials
      • Ophthalmic morbidity might warrant use
  • Topical antifungal agents can reduce chronic presence on mucosa.
    • Utility and safety of topical antifungal treatment has also been questioned (Cochrane Database Syst Dis 2011; 8:CD008263).
      • Based on 5 studies
  • Leukotriene receptor antagonists to reduce allergic reaction
    • Montelukast (Singulair)
    • Oral antihistamine might potentiate the effect.

Surgery

  • Endoscopic removal of polyps and inflammatory material (Curr Opin Allerg Clin Immunol 2012; 12:629)
    • Establish aeration and drainage of involved sinuses.
    • Valuable first step in treatment
    • Remove allergic mucin.
  • Functional endoscopic sinus surgery
    • Anterior and posterior ethmoidectomy
    • Sphenoidotomy
    • Frontal sinus trephination

Other management considerations

  • Saline nasal lavage to reduce fungal load
  • Allergic immunotherapy can reduce hypersensitivity (Curr Opin Allerg Clin Immunol 2012; 12:629).

Common treatment responses, follow-up strategies

  • Improvement takes several days to a week or more.
  • In 6 cases of orbital involvement with proptosis, there was no recurrence after treatment with mean follow-up of 34 months (range 8–48 months) (Am J Ophthalmol 1999; 127:189).
    • One patient had severe, but reversible, visual loss.
    • Two patients had limited extraocular motility, one with diplopia; all was reversible.
  • Another 3 cases of orbital involvement remained disease free during follow-up ranging 12–36 months (OPRS 2000; 16:72).
  • Can be chronic disease, with periods of exacerbation

Preventing and managing treatment complications

  • Morbidity of antifungal medications
  • Morbidity of steroid medications

Disease-related complications

Invasive inflammatory mass can produce permanent deficits if not treated.

Historical perspective

Katzenstein proposed an allergic form of chronic fungal sinusitis in 1983 (J Allergy Clin Immunol 1983;72:8).

References and additional resources

  1. Klapper SR, Lee AG, Patrinely JR, Stewart M, Alford EL: Orbital involvement in allergic fungal sinusitis. Ophthalmology. 1997; 104:2094.
  2. Han JK: Subclassification of chronic rhinosinusitis. Laryngoscope. 2013; 123:S15-27.
  3. Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus sinusitis: a newly recognized form of sinusitis. J Allergy Clin Immunol. 1983; 72:89-93.
  4. Sridhar J, Lam BL, Sternau L: Neuro-ophthalmic manifestations of fungal disease associated with posthurricane environment. J Neuro-ophthalmol 2012; 32:197.
  5. Carter KD, Graham SM, Carpenter KM: Ophthalmic manifestations of allergic fungal sinusitis. Am J Ophthalmol. 1999; 127:189.
  6. Chang WJ, Tse DT, Bressler KL, Casiano RR, Rosa RH, Johnson TE: Diagnosis and management of allergic fungal sinusitis with orbital involvement. Ophthal Plast Reconstr Surg. 2000; 16:72.